Cor Vasa 2017, 59(1):e85-e91 | DOI: 10.1016/j.crvasa.2017.01.015

MitraClip: Catheter-based treatment of mitral regurgitation

Tomáš Ondrúš^a,b,*, Martin Pěnička^b, Martin Kotrč^c, Marc Vanderheyden^b, Jozef Bartunek^b

^a Interní kardiologická klinika, Lékařská fakulta Masarykovy Univerzity a Fakultní nemocnice Brno, Brno, Česká republika

^b Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgie

^c Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Mitral regurgitation (MR) is the second most prevalent heart valve disease requiring surgery. Despite the evidence of unfavourable prognosis, around half of patients with severe MR are not referred for surgery due to high per-operative risk. MitraClip (Abbott Vascular-Structural Heart, Menlo Park, California, United States) implantation is an emerging percutaneous technique with edge-to-edge mitral valve (MV) repair inspired by the Alfieri surgery. Favourable safety profile together with improvement of functional status and decrease of MR severity in high-surgical-risk patients have been demonstrated in randomized clinical trials and "real-world" registries for both primary and secondary MR. Our own data confirmed its safety and efficacy compared to minimally invasive MV surgery in treatment of functional MR in population with severe systolic heart failure.

Keywords: Catheter-based treatment; MitraClip; Mitral regurgitation

Received: November 30, 2016; Accepted: January 12, 2017; Published: February 1, 2017  Show citation